three of the four sites affected by NS3 occurs in trans, whereas processing at the carboxy terminus of NS3 is a cis event Ser in cis (Pizzi et al., 1994; Failla et al., 1996) . The HCV genome encodes, within the NS3 gene, a serine
Introduction functions can be engineered have emerged as a means of Hepatitis C virus (HCV) is commonly accepted to be the generating conformationally defined structures with potential major etiological agent of both parenterally transmitted and as pharmacophores Zhao et al., 1995) . sporadic non-A non-B hepatitis (Choo et al., 1989; Kuo et al., In nature, immunoglobulins are unsurpassed as molecules for 1989). It is estimated that this virus infects 100-200 million generating ligands for practically any target, especially as their people worldwide and can lead to chronic and potentially lifevariable regions can be displayed on the surface of filamentous threatening infections; liver cirrhosis and primary liver cell phage, increasing their potential even further (reviewed by carcinoma can result in premature death in a substantial Winter et al., 1994) . Antibody variable domains can provide number of infected individuals (Chien et al., 1992) . Protective a very useful source of structural templates for designing low immunotherapy for HCV infection is not available and intermolecular weight lead compounds based on their compleferon treatment is of only limited efficacy (Weiland, 1994) . mentarity-determining regions (CDR) (Dougall et al., 1994 ; For these reasons, a thorough dissection of the HCV life cycle Sollazzo, 1995) . In order to generate pharmacophore models, and the identification of targets for anti-viral therapies are smaller sized antibody-derived fragments could be the important goals. The viral genome is~9400 nucleotides long molecules of choice as their binding activities can be focused encoding a precursor polyprotein (Figure 1 ) of 3011 amino on a smaller surface area. acids (Kato et al., 1990; Choo et al., 1991; Takamizawa et al., Attempts were made to reduce the size of the minimum 1991; Grakoui et al., 1993) . The enzymatic cleavage of the antibody fragment required for antigen binding. This led to polyprotein precursor produces structural proteins and enzymes the design of a 'minimized' V H domain molecule, the minibody that are essential to the life cycle of HCV (Tomei et al., 1993) . (Pessi et al., 1993; Tramontano et al., 1994) and the 'camelized' These proteins are released from the precursor polyprotein antibody (cV H ), a modified human V H domain obtained through by cellular proteases in association with membranes of the mimicking camel heavy chains for use as a small recognition endoplasmic reticulum (Hijikata et al., 1991) , whereas all proteolytic cleavages downstream of the non-strucural gene 3 unit (Davies and Riechmann, 1994; . Cleavage between NS2 and NS3 (e) is mediated by the NS2/NS3 protease activity. NS3 protease cleaves between NS3 and NS4A (cis cleavage), NS4A and NS4B, NS4B and NS5A and NS5A and NS5B (arrowheads) . Amino acid number and substrate sequence at which cleavage occurs are indicated.
Molecules specific for hapten, protein and peptide ligands with that modification of the N-terminus could interfere with interaction with NS4A co-factor (Failla et al., 1995; Kim et al. , affinities in the micro-nanomolar range were isolated from a repertoire of phage-displayed cV H with randomized CDR3 1996). To construct NS3-myc, plasmid pT7-NS3 (1027-1206) encoding the HCV BK strain NS3 protease domain from (Davies and Riechmann, 1995) . These results have been further validated by determining the X-ray structures of the natural residue 1027 to 1206, was used as a template for PCR amplification. Fusion of the myc epitope EFEQKLISQQDLG Camelidae molecules (Desmyter et al., 1996; Spinelli et al., 1996) , which provided the ultimate experimental evidence that to the C-terminus of the protease domain was obtained by using oligo-myc and NS3up as PCR primers (oligo-myc: V H -derived molecules represent the smallest natural immunoglobulin based recognition unit and open up new possibilities GCTAGCCCAGGTCTTCTTCAGAGATCAGTTTCTGCTC-GAATTCCCGCATAGTAGTTTCCATGGA; NS3up: GCATAfor generating and engineering macromolecules with highly specific binding properties. CATATGGCGCCCATCACGGCC). The PCR fragment was digested with NdeI and cloned into pT7-7 vector digested From the analysis of the X-ray structure of NS3 protease, it was predicted that the design of low molecular weight with NdeI and SmaI. The resulting pT7-NS3-myc was fully sequenced to ensure that no mutations had been introduced by inhibitors would be a very challenging task owing to the relatively featureless appearance of the substrate binding PCR. To induce expression of the protease, E.coli BL21 cells were transformed with pT7NS3-myc and grown at 37°C in groove (Kim et al., 1996) . With a view to studying both the function of HCV protease and the future design of small LB medium to a density of 0.9 OD; 400 µM IPTG were added and cells were grown for a further 4 h at 23°C. Cells were molecule inhibitors of its enzymatic activity, we sought to engineer macromolecules that would bind NS3 protease and then harvested by centrifugation and pellets were resuspended in 25 mM sodium phosphate buffer, pH 6.5, 50% glycerol, 10 to study their effects on the catalytic activity of this protease and ultimately on the viral life cycle. We describe here the mM DTT, 0.5% CHAPS, 1 mM EDTA and disrupted using a standard French press. Homogenates were clarified by isolation from a repertoire of a camelized human antibody domain of one variant that binds to the HCV NS3 protease centrifugation at 120 000 g for 1 h and loaded on an HR 26/ 10 S-Sepharose column equilibrated with 25 mM sodium domain and inhibits selectively and competitively its enzymatic activity. This macromolecular inhibitor may serve as a probe phosphate, pH 6.5, 3 mM DTT, 0.5% CHAPS, 10% glycerol (equilibration buffer) operating at 2 ml/min. The protease was for further characterizing the role this enzyme plays in HCV replication and as a basis for the development of anti-viral eluted with equilibration buffer containing 1 M NaCl and dialyzed 1:100 for 8 h at 4°C against equilibration buffer. compounds. Also, the results reported here may provide clues for engineering improved small recognition unit enzyme After this step the protease was 60% pure as judged by Coomassie-stained SDS-PAGE. The protease-containing soluinhibitors.
tion was made 50% in glycerol content and kept at -20°C Materials and methods until use. The protease was immobilized on anti-myc coated Microbiological and recombinant DNA techniques Dynabeads (see below) and extensively washed with SLB. In order to check whether the immobilized protein was still Microbiological and recombinant DNA methods were carried enzymatically active, an aliquot of protease-bound Dynabeads out according to standard protocols (Ausubel et al., 1994) or as was incubated for 6 h in SLB buffer containing 100 µM recommended by suppliers. Oligonucleotides were synthesized substrate peptide Ac-DEMEECASHLPYK. Cleavage of this using an Applied Biosystems (Foster City, CA) 380B synthespeptide was verified by subsequent HPLC analysis of the izer. Phage manipulation and Escherichia coli electroporation solution. were carried out as described previously (Martin et al., 1994; Davies and Riechmann, 1995) . Nucleotide sequences were NS3 protease assays determined using Sequenase (United States Biochemical, Assays were performed in 50 mM Tris, pH 7.5, 1% CHAPS, Cleveland, OH) according to the supplier's recommendations.
15% glycerol, 0.1 mM DTT using 20 nM recombinant NS3 The design of cV H wild type has been described previously protease purified from E.coli as described previously Riechmann, 1994, 1995) . (Steinkühler et al., 1996a) . The protease was preincubated for Construction, expression and partial purification of NS3-myc 15 min with a 14-mer peptide corresponding to the central protease domain of the protease co-factor NS4A with the sequence GSVVIVGRIILSGR . To 60 µl of assay The choice of fusing the myc epitope to the C-terminus of NS3 protease 20 kDa fragment was dictated by the assumption mix, up to 6 µl of cV H E2 solutions (or corresponding amounts of buffer) were added and incubated for a further 30 min at The beads were then blocked with 3% (w/v) E.coli bacterial extract in SLB, which was more efficient than non-fat milk or 25°C. Reactions were started by adding 40 µM substrate peptide Ac-DEMEECASHLPYK-NH 2 and stopped by adding BSA as a scavenger reagent, and washed once again before use. Then~10 11 TU (transducting units) of the cV H library in 40 µl of 1% TFA at Ͻ20% conversion. Samples were analyzed by HPLC using a Merck-Hitachi chromatograph equipped 100 µl SLB were added to the beads and affinity-selected for 3 h at 23°C in the presence of 3% E.coli bacterial extract with an autosampler, column oven and fluorescence detector. Samples of 45-90 µl were injected on to a reversed-phase and 10 11 UV-killed f1 phage particles as a blocking agent. Subsequently, the beads were washed 10 times and resuspended HPLC cartridge column (LiChrospher C18, 5 µm, 0.4ϫ7.5 cm, Merck) equilibrated with 90% solvent A (H 2 O-0.1% TFA) in 100 µl of SLB. The suspension was loaded on to 700 µl of a 30% sucrose cushion and the beads were collected by and 10% solvent B (acetonitrile-0.08% TFA) and operating at a flow rate of 2.5 ml/min. A 10-40% gradient of solvent B at applying a magnetic field (Dynal, MPC). This step was repeated a second time before acidic elution of the bound phage with 5%/min was used to separate cleavage fragments. Peaks were detected by monitoring tyrosine fluorescence (excitation at 260 0.1 M Tris-glycine buffer (pH 2.2). Following neutralization of pH and phage amplification in TG1 cells, the selection was nm, emission at 305 nm). Cleavage products were quantified by integrating chromatograms with respect to samples in which repeated four times using the same input of purified phage as in the first round. A depletion step on to the anti-myc mAb 100% conversion was achieved by 12 h of incubation in the presence of 2 µM protease.
9E10-coated beads was carried out after each enrichment cycle to counter-select for phage interacting with the matrix devoid IC 50 values were calculated by fitting inhibition data to Equation 1 using Kaleidagraph software:
of protease. As a measure of the efficacy of this counterselection, we estimate that~50% of input phage population is Activity (%) ϭ (maximum activity)/{1 ϩ ([I]/IC 50 ) S } (1) recovered after the depletion step. where [I] is the cV H E2 inhibitor concentration, maximum Expression and purification of cV H activity is that of the enzyme in the absence of inhibitor and
The V H encoding expression plasmids were transformed in S is the slope factor of the curve.
TG1 E.coli strain bearing the plasmid pDMI1 which expresses Reversibility of inhibition was assessed by dilution experiLacI (kind gift from Dr Bujiard, University of Heidelberg). ments. Briefly, NS3 protease was preincubated with cV H E2 at Cells were grown in fortified SB medium (Power et al., 1992 ) a concentration of 4-5ϫIC 50 as described above. After 30 in a bench-top fermenter (MFS, SAVI, Italy) at 27°C; the min, half the sample was diluted 10-fold and in both samples stirring rate was set at 500 r.p.m., the pH was kept between activity was determined and compared with the activity of a 7.0 and 7.5 and the air flow was fixed at 0.5 Nlt/min (l/min sample incubated with a buffer blank and a sample incubated of nitrogen equivalents). When the culture A 600 reached 2.0, from the beginning with a 10-fold diluted inhibitor concentraexpression was induced by addition of 500 µM of IPTG and tion. Inhibition was defined as reversible if more than 75% of the air flow was increased to 1 Nlt/min, culture was continued activity was recovered upon dilution. Inhibition mechanisms for 6 h (corresponding to a final A 600 of 5.0) and cells were determined by performing substrate titration experiments were collected by centrifugation. The pellet was immediately using concentrations of substrate peptide between 15 and 250 resuspended in 50 ml (1/20 of the original volume) in 30 mM µM (K m /3.3 and 5ϫK m ) in the absence and presence of 125 Tris, pH 7.4, 1 mM EDTA, 20% sucrose and left on ice for and 250 nM of cV H E2. Initial rates of cleavage were determined 30 min. Cells were centrifuged (20 min at 2500 g) and on samples with Ͻ20% conversion. Kinetic parameters were supernatant 2 was kept. The pellet was resuspended in 50 ml calculated from least-squares fit of initial rates as a function of pre-cooled 5 mM MgSO 4 and incubated for another 30 min of substrate concentration with the help of Kaleidagraph or at 4°C. The solution was centrifuged and the supernatant was Sigmaplot software, assuming Michaelis-Menten kinetics. K i pooled with supernatant 2, filtered and purified using IMAC and K ii values were calculated by re-fitting the data to a (Hochuli et al., 1987) . modified Michaelis-Menten equation:
Gel filtration chromatography
Gel filtration experiments were run on a Pharmacia FPLC system, with a Superdex-75 analytical column equilibrated in Affinity selection TBST containing 10% glycerol and 0.1 mM DTT. The calibThe library used for the selection was a kind gift from Dr ration run was done with a Pharmacia Biotech LMW gel L.Riechmann (MRC, Cambridge, UK). Briefly, the library was filtration calibration kit, which includes the following markers: constructed by inserting randomized (NNG/C) oligonucleotides dextran blue, bovine serum albumin, ovalbumin, chymotrypin the region corresponding to CDR3 of prototype cV H between sinogen and RNase corresponding to 200, 67, 43, 25 and 13.7 residues 98 and 103 (Brookhaven Protein Data Bank, 1VHP) , kDa, respectively. shown in Figure 2 . The library contained a total of~10 8 In vitro translation of NS3 and substrate transformants having insertions ranging from 5 to 12 residues in length (for details, see: Davies and Riechmann, 1995) .
DNA fragments derived from HCV-BK strain cDNA were inserted downstream of the 5Ј untranslated region of encephaloDynabeads M-280 sheep anti-mouse antibody (Dynal) were coated with 90 pmol of anti-myc mAb 9E10 according to the myocarditis virus and under the T7 promoter in the pCite-1 vector (Novagen) in the appropriate translational reading frame supplier's instructions. A saturating amount of myc-tagged NS3, 400 pmol in selection buffer (SLB: 15% glycerol, 0.1 and followed by a termination codon. The plasmids pCiteNS3-4A∆cut and pCiteNS5AB∆C51, expressing the HCV proteins mM DTT, 50 mM NaCl, 0.5% CHAPS, 10 mM Tris, pH 7.5,) was used for immobilization on to the anti-myc mAb 9E10.
NS3-4A with a mutated cleavage site and NS5AB from residue 1965 to residue 3010, respectively, have been described After a 2 h incubation at room temperature, the unbound NS3 was eliminated by five washes (100 µl, 1 min each) with SLB.
previously (Steinkühler et al., 1996a,b; Tomei et al., 1996) . et al., 1996) , PDB entry 1VHP (Bernstein et al., 1977) , showing the close spatial proximity of CDR3 (magenta) and residue Ile 47 (green). The figure was drawn using RIBBONS (Carson, 1987) .
In vitro transcription was done with T7 RNA polymerase in sequence and length (5-12 residues) and displayed as fusion with the pIII protein of fdCAT (Davies and Riechman, 1995) . (Promega). The transcripts were translated for 1 h at 30°C in Four rounds of selection were carried out and subtractive steps the presence of [ 35 S]methionine using RNA-dependent rabbit were included between rounds. A depletion step consists of reticulocyte lysate (Promega). Cleavage of labelled precursor incubating the amplified library with the matrix, including all was assessed by SDS-PAGE on 10% gels and exposed on the reagents but devoid of NS3 20 kDa fragment. Because NS3 Phosphorimager from Molecular Dynamics.
protease requires detergent and kosmotropic agents for optimal Elastase and kallikrein assays activity (Steinkühler et al., 1996a) , affinity-selection steps The pancreatic porcine elastase (PPE), its substrate (Me-o-Sucwere carried out for 4 h at room temperature, in the presence Ala-Ala-Pro-Val-pNA) and the pancreatic porcine kallikrein of 15% glycerol and 1% CHAPS detergent, under mild reducing (PPK) were purchased from Calbiochem. The PPK substrate conditions (0.1 mM DTT and in a nitrogen atmosphere), to Chromozym (D-Pro-Phe-Arg-pNA) was purchased from maintain adequate conditions for the enzymatic activity but Boehringer Mannheim. The PPE assay was performed in a avoiding disruption of the V H disulfide linkage. Under these 96-well plate, in 50 mM TES, pH 7.5, 500 mM NaCl, 0.05% buffer conditions the protease is active for 3-4 h, judged Triton X-100, 5% DMSO buffer; the enzyme was added to adequate to carry out the affinity selection. the final concentration of 0.5 µg/ml and substrate to 500 µM.
Following selection, 42 phage clones from the fourth round Samples were tested in a 100 µl final volume and after 75 were cultured, concentrated by PEG precipitation, their ssDNA min of incubation at room temperature under constant agitation, extracted and the CDR3 amino acid sequence was determined the OD was read at 405 nm. The PPK assay was performed by DNA sequencing (Table I) . Some of these putative NS3 in 120 mM Tris, pH 8.0, 0.01% Triton X-100, 5% DMSO; ligands were present as multiple isolates; particularly striking the concentration of the protease and its substrate were 50 nM was clone cV H E2 that represented the major component (20/ and 100 µM, respectively. After incubation for 1 h at 23°C 42) of the phage population. Its CDR3, considerably rich in under agitation the OD was recorded at 405 nm.
proline residues, shows a suggestive similarity to other isolates, albeit the lengths of their CDR3 differ greatly. Because the Results library was constructed using randomized oligonucleotides In order to carry out affinity selection of randomized CDR3 according to the scheme NNG/C, the relatively high percentage variants of cV H domains displayed on filamentous phage, it of Pro residues observed here is not due to a bias in the was fundamental to engineer the target NS3 protease 20 kDa repertoire, as suggested also by the sequence of other isolates minimal domain that can be expressed in E.coli and purified recovered from a different study (Davies and Riechmann, in large quantities (Steinkühler et al., 1996a) to allow its 1995). We decided to study some of these clones further with immobilization on to a solid-phase matrix in a bioactive the aim of identifying protease inhibitors. To this end, the conformation. To this end we fused a myc-tag peptide DNA fragments encoding the variable region of the isolated (EFEQKLISQQDLG) to the C-terminus of HCV NS3 domain, cV H of some bona fide NS3 ligands were excised from the thus achieving an enzyme variant which retains catalytic phage RF dsDNA by digestion with XhoI and BstEII and activity when immobilized through the anti-myc mAb 9E10 subcloned into pUCV H -myc vector, suitable for expression in (data not shown). The NS3 affinity matrix was prepared by the periplasmic space of E.coli (Davies and Riechmann, 1995) . saturating anti-mouse-coated magnetic beads with a complex Next, the cV H proteins bearing the myc epitope and the (His) 6 of myc-tagged NS3 protease and the tag-specific mAb 9E10.
tag genetically fused to their C-termini were purified by IMAC As a source of ligands we used the cV H library in which the (Hochuli et al., 1987) before testing. As a preliminary screen for inhibition activity, we used the in vitro translation assay CDR3 of prototype cV H domain (Figure 2) , randomized both residual enzyme activity as a function of cV H E2 concentration using a small fluorescent substrate at a concentration of 40 µM. It is worth noting that the IC 50 of cV H E2 was not affected (Steinkühler et al., 1996b) in which the in vitro transcribed RNAs encoding the 20 kDa NS3 fragment and one of the by the co-factor NS4A and was estimated to be 300 nM ( Figure 5 ). Because cV H E2 activity is not inhibited by NS4A substrates, NS5AB, are incubated in the presence of fixed amounts of cV H proteins. The purified proteins encoded by peptide and vice versa, it appears that the selected ligand can bind both forms of the enzyme, both as a free species and as several constructs were tested at 1.5 µM in triplicate samples and only cV H E2 was revealed as an inhibitor of the protease a heterodimer complex. It was also important to establish the reversibility of the inhibition activity, assessed by an assay in activity (Figure 3) . At this concentration, most of the molecules tested showed little or no activity (0-30% inhibition), within which we pre-incubated the enzyme with 1.5 µM concentration of the cV H E2 inhibitor (five times its IC 50 value) followed by the range of non-specific inhibition given by the non-selected, negative control cV H N5 and therefore were not pursued further.
a 10-fold dilution and determination of the residual enzymatic activity ( Figure 6 ). The results were consistent with reversible On the other hand, cV H E2 appeared to be a relatively potent inhibitor, deserving additional characterization.
inhibition as we recovered more than 80% of the enzyme activity upon dilution of the complex. To establish the mechanIn order to determine the apparent molecular weight of cV H E2 under NS3 protease assay buffer conditions, we carried ism of action of the cV H E2 inhibitor, substrate titration experiments were performed in the absence and in the presence out gel filtration FPLC in this buffer, except that the glycerol concentration was lowered to 10% (the maximum compatible of 125 and 250 nM of cV H E2 ( Figure 7) . By fitting the experimental data to a modified Michaelis-Menten equation with chromatography). The protein migrates as a dimeric species with an apparent molecular weight of 25 kDa ( Figure  (Equation 2 ), the dissociation constants of the enzyme inhibitor Fig. 7 . Determination of the inhibition mechanism. To determine the purified cV H E2 inhibitor (duplicate), 40 µM substrate and 10 µM NS4A comechanism of inhibition of cV H E2, substrate titration curves were recorded factor. Percentage of residual activity (y-axis) was determined as function of in the absence and in the presence of two different concentrations of inhibitor concentration (x-axis) and the IC 50 value derived.
inhibitor: 250 nM (circles), 125 nM (squares), no inhibitor (diamonds), and the values of K i (enzyme-inhibitor complex dissociation constant) and K ii (ternary enzyme-inhibitor-substrate complex dissociation constant) derived by fitting the experimental data to a modified Michaelis-Menten equation.
selectivity by testing cV H E2 on two commercially available serine protease assays, namely porcine elastase and kallikrein. Neither of these enzymes was inhibited to any measurable extent upon incubation with a concentration of cV H E2 corresponding to a 5-30-fold excess of the inhibitor/substrate ratio (data not shown), indicating a substantial level of selectivity. Finally, because of the lack of cell-based replication systems for HCV, in order to determine if cV H E2 was active on the entire (70 kDa) NS3 gene product (including the helicase domain) and on the natural substrate, we exploited the in vitro translation assay described previously (Tomei et al., 1993) as a surrogate for a biological assay. In this experiment (Figure  8) , cV H E2 inhibits 70 kDa-borne proteolytic activity with an apparent IC 50 of~1 µM, 3.3-fold above the value determined by the activity titration assay with the (13-mer) synthetic substrate.
Discussion
Because of the importance of HCV as a human pathogen and the lack of an effective treatment (Weiland, 1994) , there is a proteins (Korant, 1988; Kräusslich and Wimmer, 1988) . These observations have led to an ever increasing interest in proteases as potential therapeutic targets. Previous studies have indicated complex (K i ) and of the ternary enzyme-inhibitor-substrate complex (K ii ) were determined. We obtained K i ϭ 150 nM that the HCV NS3 protease activity is required for processing the non-structural proteins NS3, NS4 and NS5 in addition to and a very high value for K ii . This indicates that the cV H E2 inhibitor binds to the free enzyme but has virtually no acting cis at its C-terminus to release itself from the polyprotein precursor, in a similar fashion to the viral protease of flaviaffinity for the enzyme-substrate complex, as expected for a competitive inhibitor. Probably the selected molecule binds to viruses and pestiviruses (Miller and Purcell, 1990) . Proteolytic events mediated by the NS3 protease are likely to be absolute the enzyme active site or to a nearby epitope, thus hampering the substrate entry, but in any case its binding site is far from requirements for the generation of an active viral replication apparatus. Because NS3 is crucial for the HCV polyprotein the NS4A binding site. We also determined that cV H E2 was not cleaved by NS3 after overnight incubations with high processing and its flaviviral analog has been shown to be essential for viral replication (Chambers et al., 1990) , the NS3 concentrations (30 µM) of NS3 (data not shown), demonstrating that the observed inhibition of NS3 by cV H E2 is not due protease has become the focus of intensive study to develop anti-HCV drugs, as emphasized by two recent reports on the to cleavage of a competitor substrate. Next, we checked less well defined connecting loops and turns . The general topology of two pleated β-sheets and the conformation of the hypervariable loops H1 and H2 were shown to be very similar to those of V L -associated V H domains (Figure 2) .
Usually, the G47I mutation does not affect antigen binding or specificity Riechmann, 1995, 1996) ; however for cV H E2 we observed a 20-fold reduction in potency which is not dependent on dimerization. The cV H E2 protein forms dimeric species independently from the nature of its residue 47 (G or I). In the light of recent structural data, it is conceivable that in the absence of cognate V L some CDR3 structures can be affected by the nature of residue 47, which in turn may promote dimerization. In fact, the NMR structure of the parental cV H , which has a shorter CDR3 than cV H E2 (Figure 2 ), demonstrated that it is a stable monomeric protein . In addition, that dimerization may be dependent on the nature of CDR3 is also supported by the 1.85 Å X-ray structures of antigen-free llama V H domain (Spinelli et al., 1996) and by the 2.5 Å crystal structure of a camel V H in complex with its antigen, lysozyme, as reported recently (Desmyter et al., 1996) . Compared with human and mouse V H domains, there are no major backbone rearrangements in the V H framework, but the architecture of the region of V H that interacts with a V L in a conventional F v is different from any previously seen. The camel antibody has a very long penetrates into the lysozyme active site.
with the protease and NS4A, and subsequently the substrate was added and incubated further, allowing conversion to occur. The percentage conversion
The CDR3 segment that penetrates deeply into the active (y-axis) was determined by densitometric analysis of the radiolabeled site of lysozyme provides most of the binding energy; unfortuproduct after separation by SDS-PAGE. nately, this is unlikely to be the case for the NS3/cV H E2 interaction, as suggested by the analysis of the X-ray structure of the NS3 specificity pocket (Kim et al., 1996) . Nonetheless, structural determination of NS3 protease domain (Kim et al., 1996; Love et al., 1996) . In particular, it was argued that the cV H E2 may still be a useful tool for guiding the synthesis of CDR3 peptido-mimetics as shown successfully, albeit with an absence of some conserved loops, in the NS3 protease, renders its substrate binding site relatively shapeless, thus it was expected loss in potency (Smythe and von Itzsein, 1994) . In the absence of structural data, there are two considerations anticipated that the making of substrate-based small molecule inhibitors will be a daunting task (Kim et al., 1996) . For these that can be made about the mechanism of inhibition for cV H E2: (i) the inhibitor binds NS3 both as a free enzyme and as a reasons, we anticipate that a deeper understanding of the NS3 surface properties and the availability of biological tools for heterodimeric complex with NS4A; (ii) the mechanism of action is that of a competitive inhibitor. It is therefore likely studying it will have a substantial impact on the development of effective inhibitors. Here we report the affinity selection that cV H E2 binds to the enzyme active site or to a nearby epitope, thus hampering substrate entry, but in any case its and characterization of cV H E2, a camelized V H domain (Davies and Riechmann, 1994) , that is a relatively potent and selective binding site is far from the NS4A binding site. It should also be emphasized that the inhibitor is not cleaved by NS3, which competitive inhibitor of the NS3 protease activity.
The Camelidae is the only taxonomic family known to can be a consequence of the absence of a suitable Cys residue within the CDR3 sequence or a unfavorable geometry (as a possess functional heavy-chain antibodies, devoid of light chains (Hamers-Casterman et al., 1993) . V H domains lacking substrate) of the CDR backbone structure. Taking these results together, it is tempting to propose that to design candidate their V L partners have been bacterially expressed and shown to be able to bind antigen specifically (Ward et al., 1989) . molecules (good building blocks) for the selection of more general enzyme inhibitors, it would be wise to engineer Camelization of a human V H domain (V H -P1) to mimic camelid heavy chains was achieved by introducing the mutations G44E, cV H constructs with a long CDR3, part of which could be randomized to fit the target enzyme active site cleft whereas L45R and W47G Riechmann, 1994, 1996) that are crucial for reducing the affinity for the cognate V L domain an invariant component (which would act as an additional framework) could be designed based on the natural camel (Chothia et al., 1985) . Camelizing mutations also made the structural determination of this cV H by NMR spectroscopy antibody (Desmyter et al., 1996) , to shield the former V L interface, thus avoiding dimerization. In this respect it may possible , except that residue 47 was mutated in isoleucine, which yields better expression and higher also be relevant to point out that by using a minibody scaffold (Pessi et al., 1993) having shorter CDRs (six residues) for the stability compared with the G47 containing V H domains (Davies and Riechmann, 1994; . The solution structure selection of NS3 inhibitors, we were able to recover a ligand of comparable potency but showing a non-competitive inhibition of the cV H showed well defined regions of β-structure and
